How Math, Statistics, and Artificial Intelligence Can be Used to Develop Treatments for Major Diseases: Quantitative Medicine at the Critical Path Institute
C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the Symptoms of Major Depressive Disorder Momentary Assessment (SMDDMA) C-Path’s Patient-Reported Outcome (PRO) Consortium announced that it has been awarded a U.S. Food and Drug Administration (FDA)
C-Path Launches Consortium to Accelerate Medical Product Development in Sickle Cell Disease September is National Sickle Cell Awareness Month TUCSON, Ariz., Sept. 17, 2020 — The Critical Path Institute (C-Path) today
October 28, 2021-October 29, 2021 View Now | October 28-29 | International Neonatal Consortium 2020 Virtual Workshop This two-day virtual workshop, hosted in collaboration with EMA, will bring together hundreds of INC consortia members and collabo
October 10, 2020 Watch Now: Accelerating Drug Development for Rare Diseases through Data Sharing and Analysis Webinar Despite increasing numbers of drug targets and technologies, rare disease drug development is frequently slowed by t
September 13, 2020 How Math, Statistics, and Artificial Intelligence Can be Used to Develop Treatments for Major Diseases: Quantitative Medicine at the Critical Path Institute This presentation focuses on the bridge between a person’s ultimate health in light of being affected by a debilitating disease,